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Characterising covalent warhead reactivity
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A B S T R A C T
Many drugs currently used are covalent inhibitors and irreversibly inhibit their targets. Most of these were
discovered through serendipity. Covalent inhibitions can have many advantages from a pharmacokinetic per-
spective. However, until recently most organisations have shied away from covalent compound design due to
fears of non-specific inhibition of off-target proteins leading to toxicity risks. However, there has been a renewed
interest in covalent modifiers as potential drugs, as it possible to get highly selective compounds. It is therefore
important to know how reactive a warhead is and to be able to select the least reactive warhead possible to avoid
toxicity. A robust NMR based assay was developed and used to measure the reactivity of a variety of covalent
warheads against serine and cysteine – the two most common targets for covalent drugs. A selection of these
warheads also had their reactivity measured against threonine, tyrosine, lysine, histidine and arginine to better
understand our ability to target non-traditional residues. The reactivity was also measured at various pHs to
assess what effect the environment in the active site would have on these reactions. The reactivity of a covalent
modifier was found to be very dependent on the amino acid residue.
1. Introduction
Covalent drugs act to inhibit enzymes irreversibly through forma-
tion of a covalent bond, typically to the reactive side chain of an amino
acid in the enzyme active site.1 Until recently, many organisations have
avoided covalent modifiers in drug discovery, due to concerns of non-
specific modification of other proteins giving rise to toxicity. However,
there is now renewed interest in covalent modifiers as drugs. Indeed
many current drugs are covalent inhibitors, but most of these have not
been designed, but discovered by serendipity. Covalent drugs include
for example β-lactam antibiotics,2 aspirin,3 clopidogrel,4 osimertinib,5
and omeprazole.6 Covalent drugs can provide advantages including an
increased residency time at the molecular target compared to “tradi-
tional reversible” inhibitors,7 which can lead to a dosing regimen,
where the concentration of the free drug does not need to be constantly
maintained above the efficacious dose as shown in Fig. 1.
By careful design of the molecule, excellent selectivity can be ob-
tained. When designing a covalent drug it may be useful to consider
binding as occurring in two distinct stages to avoid toxicity.8 First the
drug has to bind to the target via non-covalent bonds and for this it
depends on the overall structure of the binding site as is the case with a
traditional reversible drug. Then a covalent drug has to form a covalent
bond to a specific nucleophilic residue in the target. The non-covalent
binding has to be optimised through design of the overall compound
structure. However, the second part is optimised by careful selection of
the covalent warhead to make sure that it has appropriate reactivity
and orientation within the active site. The warhead should have suffi-
cient reactivity to form the covalent bond to the residue in the active
site, when held in the correct orientation by the recognition motif, but
insufficient reactivity to non-specifically react with residues in other
proteins.
Kinetic models have been introduced to explain covalent inhibition
as shown in Fig 2.9,10 In the first step, the enzyme and inhibitor form a
reversible complex (E.I). There is then a second step in which the
covalent modifier forms a covalent bond with the enzyme. In this model
the rate at which covalent bond formation occurs is defined as kinact/KI,
where: kinact is the maximum rate at which the reversible complex
forms the covalent bond (k3); and KI is defined as (k2+ k3)/k1 and is
the concentration of inhibitor which gives half the maximum rate of
covalent bond formation (E–I).
However, other factors may affect the process. For example, it is
possible in some cases that there is a direct reaction between the
covalent inhibitor and the protein without a prior molecular recogni-
tion event. In other cases the protein may have a substantial role in
covalent inhibitor bond formation.11
The main concern with covalent modifiers is their ability to bind
irreversibly to off target proteins and result in toxicological effects such
as immune responses.12 To better understand this risk, and have a
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logical approach to reduce these effects, it is important to have an
understanding of the reactivity of typical covalent warheads. Previous
assays to measure the reactivity of covalent warheads have either fo-
cused on cysteine13–15 (for example using fluorogenic probes)14 or
glutathione (using a mixture of computational [quantum mechanical]
and experimental [LCMS] approaches)12 or focused on a single type of
covalent warhead.16 By looking at a range of covalent warheads and a
range of amino acids, a better understanding of the relative reactivity
can be obtained. To this end a NMR based assay was designed which
allows the rate of reaction of any amino acid with any covalent warhead
of interest to be measured. The reactivities of a selection of common
covalent warheads were measured against cysteine and serine as these
are the most commonly targeted amino acids. A selection of other po-
tentially reactive amino acids was also investigated.
It should be noted that the reactivity of the covalent warheads
measured here was carried out in solution. However in the context of an
enzyme, molecular recognition events will constrain the warhead to a
limited set of orientations within the active site. The orientation of the
warhead will affect the rate at which it reacts with the protein. In an
ideal scenario, the warhead should be constrained in orientation to give
a favourable trajectory for reacting with the appropriate residue, which
should result in the covalent bond formation reaction occurring faster
and help reduce off target effects.16 The measurements reported here
cannot replicate the molecular recognition events, but are useful for
comparing the reactivity of different covalent warheads to a variety of
nucleophiles, which is important in selecting potential warheads.
2. Results
2.1. Kinetics assay
An NMR assay which can track the amount of the covalent warhead
in solution with an amino acid was designed. A typical assay setup is
shown in Fig. 3.
The amino acid is used at 10x the concentration of the warhead to
give the reaction pseudo first order kinetics, as the concentration of the
amino acid remains in large excess of the warhead throughout the re-
action and therefore can be considered to be constant. To ensure that
the covalent warhead was reacting with the sulfur of the cysteine or the
hydroxyl of the serine the amine group was protected with a BOC group
and the carboxylic acid was protected as a methyl ester.
As the reaction proceeds the amount of the covalent warhead is
reduced and this can be measured as the decrease in the integral of the
NMR peaks corresponding to the warhead as seen in Fig. 4. The peaks
selected for monitoring by NMR are those where the chemical shift will
change substantially between the substrate and the product. Typically
these were peaks corresponding to atoms associated with the warhead;
however, peaks in the attached phenyl ring can also be used when re-
quired. A suitable relaxation delay was included in the experimental
design, to minimise saturation effects. All this ensures that the experi-
ments are quantitative. The rates of reaction were relatively slow for
most reactions, meaning the setup, data acquisition and mixing times
were not significant and would not affect the rate determination, which
is determined by the gradient of the line obtained.
By then plotting the natural log of the integral of these peaks against
time (Fig. 5) a straight line is achieved where the gradient corresponds
to the rate of the reaction. By doing this for each peak corresponding to
the covalent warhead in the NMR spectra an accurate measure of the
reactivity can be achieved.
Fig. 1. (a) With a non-covalent drug (left) the con-
centration must usually be kept above the minimum
efficacious dose (purple line) to have an effect. The
concentration and target inhibition are directly re-
lated. (b) With a covalent drug once the covalent
bond has formed it is not necessary to maintain the
free drug (dashed line) in the body at high con-
centrations as the drug is irreversibly bound to the
target (solid line) until the target is degraded. In this
case the drug concentration is not directly related to
target inhibition. (For interpretation of the refer-
ences to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 2. The kinetic models used to explain covalent inhibition.
Fig. 3. An example kinetic assay.
Fig. 4. Example NMR spectra for the reaction shown in Fig. 3 looking at one of
the vinyl protons. Over time the amount of covalent warhead is reduced and
this is observed as the area under these peaks decreasing.
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2.2. Results with cysteine and serine
The reactivity of a range of covalent warheads measured against
cysteine and serine are presented in Fig. 6. The blue points correspond
to the rate constant for the reaction with cysteine and the red points the
rate constant for the reaction with serine. Each point is numbered ac-
cording to the compound in the accompany table to Fig. 6.
The reactivity of a selection of these warheads against other amino
acids which could also be targeted are presented in Fig. 7. All assays
were initially performed at physiological pH (pH=7.4). However,
many residues in active sites have perturbed pKa values which change
the reactivity to electrophiles and their protonation state. Amino acids
with a pKa where it was conceivable that the protonation state could be
substantially changed were investigated at various pHs. Histidine
(pKa=6) was investigated at pH 5 and pH 9.8 and cysteine (pKa= 8)
and tyrosine (pKa=10) were both also investigated at pH 9.8. The
results are also shown in Fig. 7. To ensure the assay is reproducible the
rate of reaction between cysteine and both the acrylamide (15) and the
vinyl sulfonamide (16) was measured three times and an average taken.
In each case the average was found to be within 7% of the measured
rates suggesting that the assay is extremely reproducible (Table 1). Due
to the time required for each experiment and the reproducibility of the
assay each experiment was performed once for other examples.
During this study we have looked at both potentially “reversible”
and “irreversible” covalent modifiers. A “reversible” covalent inhibitor
would be for example the trifluoroketone (1), the oxaborole (3) and the
nitriles (5, 7, 8, 9), where a reversible reaction could potentially re-
generate the inhibitor. The Michael acceptors (10, 11, 12, 15, 16) are
likely also reversible, albeit the rate of the reverse reaction is likely to
be very slow and in many cases essentially irreversible. The irreversible
warheads are the β-lactams (2, 4, 6), where hydrolysis of the inhibitor
from the amino acid residue could potentially happen, but would pro-
duce a modified and unreactive version of the inhibitor.
It is instructive to compare reactions with cysteine and serine. There
is a very different order in reactivity of the different warheads with the
two residues. This can be largely explained as serine is a much “harder”
nucleophile than cysteine and tends to react faster with the “harder”
electrophiles (for example the benzoxaborole (3) and the sulfonyl
fluoride (13) are “harder” electrophiles). In contrast, the Michael ac-
ceptors 12, 15 and 16 are softer electrophiles and react more rapidly
with the “softer” cysteine. The cysteine reacts with these Michael ac-
ceptors at least 2 orders of magnitude more rapidly than serine does.
The reactions of cysteine with 15 and 16 are significantly faster than
any of the other reactions that we investigated. Compound 16 was
found to react so quickly with cysteine that a rate constant could not be
measured for this reaction. The “hard” or “soft” natures of the elec-
trophiles was suitable for prediction of the relative reactivity between
cysteine and serine in the majority of cases, but in some cases, parti-
cularly in cases where the electrophile was of moderate “hardness” or
“softness” the relative reactivity was more difficult to predict and other
factors may be important.
The acrylamide warhead (12) is currently under investigation in a
range of ongoing covalent modifier drug discovery projects,17 this was
found to react 3 orders of magnitude faster with cysteine than with
serine suggesting why it is of such interest. However, this is not ob-
served with the closely related compound 10 which was found to have
very similar reactivity between cysteine and serine. This may be be-
cause the nitrogen in compound 10 alters the reactivity of the double
bond or it may be that the nitrogen is able to act as a general base and
deprotonate the serine to make it more reactive. Compound 11 also had
similar reactivity with both cysteine and serine.
The nitriles (5, 7, 8) appear to react similarly with both cysteine and
serine, but have relatively slow rates. The sulfonyl fluoride (13) was
quite reactive to both cysteine and serine. The carbamate (14) was
significantly more reactive to cysteine than serine.
Compound 2 (a penicillin) was found to react with serine too slowly
for a rate to be measured. This is interesting because penicillins, like
compound 2, are known to react with a serine residue in vivo to have an
effect. This shows how important the non-covalent binding and or-
ientation of the warhead in active site plays in the ability of covalent
drugs to form a covalent bond to their target. The β-lactams 4 and 6
were more reactive than the penicillin with both cysteine and serine.
Interestingly compound 6 was moderately reactive with serine. This
may be due to the nitrogen lone pair being less available due to delo-
calisation into the phenyl ring, increasing the reactivity of the carbonyl.
A wide range of different covalent warheads, with different re-
activities, are found in clinically used drugs. This shows that the re-
activity of the warheads depends on a number of factors, including the
amino acid residues found in the target and the recognition motif that
gives rise to the initial non-covalent binding interaction and selectivity
with the target.
2.3. Other amino acids
Tyrosine, arginine, lysine, threonine and histidine were identified as
amino acids that might also be targetable using covalent inhibitors. To
investigate this, three covalent warheads which displayed the overall
trend of being more reactive against cysteine than serine in Fig. 6 were
selected and their reactivity measured against these amino acids. It was
found that all amino acids were targetable to various degrees with
histidine being as reactive as serine while tyrosine was found to be far
less reactive. It is likely that other covalent warheads could be identi-
fied that are better at targeting these amino acids.
Amino acids where it is conceivable that there could be significantly
different protonation states in proteins were also investigated at other
pHs. Histidine (pka=6) was investigated at pH 5 and pH 9.8. Tyrosine
(pKa=10) and cysteine (pKa= 8) were also investigated at pH 9.8. As
was expected where the amino acids were more deprotonated, and
therefore more reactive, the reactions proceeded faster.
2.4. General comments
Ultimately, the ability to target a particular amino acid will depend
on both the warhead being used and on the environment in which the
residue exists.
Overall these results provide an indication of how a drug containing
a covalent warhead may be tuned to a particular project. If a covalent
compound is too reactive and is found to have toxic side effects a less
reactive warhead can be selected. Conversely, if the covalent warhead
is not reactive enough to form a bond to the target then a more reactive
warhead can be selected. Also we have derived information in under-
standing the differences between the different amino acid residues. The
relative orientation of the warhead to the nucleophile in the binding
site will also be an important factor in the success of a covalent drug,
which has not been assessed here. The advantages of this approach is
that it is simple to carry out and gives an indication of the relative
Fig. 5. Results from the example kinetic assay.
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reactivity of different warheads with different amino acid side chains.
However, it does not take account of the molecular recognition events
within an enzyme active site.
2.5. Synthesis
Some of the covalent warheads of interest were commercially
available and these were purchased. Those which were not available
were synthesised as shown in Scheme 1. The acrylamide (12) was
synthesised from aniline using acryloyl chloride and triethylamine in
dichloromethane at 0 °C. The methyl carbamate (14) was obtained
under the same conditions using methyl chloroformate, as was the vinyl
sulfonamide (15) using the sulfonyl chloride. The substituted acryla-
mide (10) was synthesised from aniline and the appropriate carboxylic
acid using propylphosphonic anhydride as the coupling reagent in tet-
rahydrofuran. The 4-β-lactam (4) was synthesised from β-phenylala-
nine using mesyl chloride and sodium bicarbonate in acetonitrile at
60 °C. The 1-β-lactam (6) was obtained from aniline using 3-
Fig. 6. The results of measuring the reactivity of covalent warheads against cysteine (blue dots) and serine (red dots). Compound numbers correspond to their
number in the graph and are numbered sequentially based on their reactivity with cysteine (1= least reactive, 16=most reactive). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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bromopropionyl chloride and potassium carbonate in dichloromethane
at 0 °C to give the amide which was then cyclised using sodium tert-
butoxide in dimethylformamide at 0 °C. The ketones (11, 16) were
synthesised from benzaldehyde using the appropriate Grignard reagent
in tetrahydrofuran at 0 °C. These were then oxidised to the ketone using
Dess-Martin periodinane. Finally, the sulfonyl fluoride (13) was ob-
tained by treating the sulfonyl chloride with TBAF in tetrahydrofuran.
The amino acids of interest were commercially available with the
exception of Boc-Arg-OMe. This was synthesised as shown in Scheme 2
using DCC.
3. Experimental
3.1. General methods
Chemicals and solvents were purchased from commercial sources
and were used without any further purification. Air and water sensitive
reactions were carried out under an inert nitrogen atmosphere in oven
dried glassware. Analytical thin-layer chromatography (TLC) was per-
formed on precoated TLC plates (layer 0.20mm silica gel 60 with
fluorescent indicator UV254, from Merck). Developed plates were air-
dried and analysed under a UV lamp (UV254/365 nm) and by staining
with permanganate or ninhydrin. Flash column chromatography was
performed on prepacked silica gel cartridges (230–400 mesh,
40–63 μm, from SiliCycle) using a Teledyne ISCO Combiflash Rf or
Combiflash Rf 200i.1H (400MHz or 500MHz), 13C (100MHz or
125MHz), and 2D NMR spectra were recorded in CDCl3, MeOD or
DMSO‑d6 using a Bruker Avance spectrometer. Proton chemical shifts
are reported in ppm relative to the residual chloroform peak
(δ=7.26 ppm), methanol peak (δ=3.31 ppm) or DMSO peak
(δ=2.50 ppm). Multiplicities are given as s (singlet), d (doublet), t
(triplet), q (quartet), qui (quintet), m (multiplet), brs (broad singlet), dd
(doublet of doublets), td (triplet of doublets), dt (doublet of triplets) or
as a combination of these. Coupling constants (J) are quoted to the
nearest 0.1 Hz. 13C chemical shifts are reported in ppm relative to the
residual chloroform peak (δ= 77.16 ppm), methanol peak
(δ=49.00 ppm) or DMSO peak (δ= 39.51 ppm). Assignment of proton
and carbon signals was achieved using COSY, HSQC and HMBC ex-
periments. LCMS analysis was performed with either an Agilent HPLC
1100 series connected to a Bruker Daltonics MicrOTOF or an Agilent
Technologies 1200 series HPLC connected to an Agilent Technologies
6130 quadrupole spectrometer, where both instruments were con-
nected to an Agilent diode array detector. High resolution electrospray
measurements were performed on a Bruker Daltonics MicrOTOF mass
spectrometer. Preparative HPLC was performed on a Gilson HPLC (321
pump, 819 injection module, 215 liquid handler/injector) connected to
a Gilson 155 UV/vis detector using Waters XBridge C18 columns
(100× 19mm, 5 µm particle size) eluting with 0.1% formic acid in
water and acetonitrile (95:5 -> 5:95) as the mobile phase.
Fig. 7. The measured rate constants for selected covalent warheads reacting with potential target amino acids.
Table 1
Activity of covalent warheads with cysteine; data in triplicate.
Covalent Warhead
k=8.38× 10−5 s−1
t1/2= 2.3 ± 0.1 h
k=6.73× 10−4 s−1
t1/2= 17.2 ± 1.2min
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3.2. Synthesis of 4-phenylazetidin-2-one (4)
3-amino-3-phenyl-propanoic acid (100mg, 0.61mmol, 1 equ) was
dissolved in MeCN (60ml) and methanesulfonyl chloride (277mg,
2.42mmol, 4 equ) and sodium hydrogen carbonate (305mg,
3.63mmol, 6 equ) were added. The mixture was heated to 60 °C and
stirred overnight. Water (10ml) was added and the mixture extracted
3x with 30ml ethyl acetate. The combined organics were dried over
MgSO4, passed through a phase separator and evaporated to dryness.
The residue was purified by flash chromatography eluting with a gra-
dient of 0–100% ethyl acetate in heptane to give 4-phenylazetidin-2-
one (80mg, 90%) as a white solid.
1H (400MHz, CDCl3): δ 7.39–7.28 (5H, m, H1, H2, H3), 6.71 (1H,
brs, H8), 4.70 (1H, dd, J=5.3, 2.5 Hz, H5), 3.41 (1H, ddd, J=14.9,
5.3, 2.5 Hz, H6a), 2.84 (1H, ddd, J=14.9, 2.5, 0.9 Hz, H6b);
13C (100MHz, CDCl3): δ 168.46 (C7), 140.33 (C4), 128.87 (C2),
128.21 (C1), 125.69 (C3), 50.42 (C5), 47.94 (C6).
Analysis is in agreement with the literature.18
3.3. Synthesis of 1-phenylazetidin-2-one (6)
To a suspension of potassium carbonate (445mg, 3.22mmol,
1.2 equ) in DCM (10ml) was added aniline (250mg, 2.68mmol, 1 equ).
The mixture was cooled to 0 °C and 3-bromopropanoyl chloride
(552mg, 3.22mmol, 1 equ) added dropwise. The reaction was stirred at
0 °C for 15min then allowed to warm up to room temperature. After
three hours LCMS showed complete conversion of aniline to the inter-
mediate so 5ml water was added and the layers separated. The aqueous
layer was extracted 3× with 15ml ethyl acetate and the combined
organic layers were dried over MgSO4, passed through a phase se-
parator and evaporated to dryness. The residue was recrystallised from
5ml 1:1 heptane: ethyl acetate to give the intermediate (520mg, 85%)
as a white powder.
MS (ESI) m/z 228.1 [M+H]+
This intermediate was dissolved in DMF (10ml) and cooled to 0 °C.
Sodium tert-butoxide (256mg, 2.68mmol, 1.2 equ) was added and the
reaction was allowed to slowly warm up to room temperature for three
hours. The solvent was removed in vacuo and the residue was dissolved
Scheme 1. Synthesis of the covalent warheads of interest.
Scheme 2. Synthesis of Boc-Arg-OMe.
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in 10ml DCM, washed with 10ml water and the aqueous layer ex-
tracted 2× with 15ml DCM. The combined organics were dried over
MgSO4, passed through a phase separator and evaporated to dryness.
The residue was purified by flash chromatography eluting with a gra-
dient of 0–80% ethyl acetate in heptane to give 1-phenylazetidin-2-one
(95mg, 24%) as a white powder.
1H (500MHz, CDCl3): δ 7.31 (4H, m, H2, H3), 7.06 (1H, m, H1),
3.56 (2H, t, J=4.5 Hz, H5), 3.05 (2H, t, J=4.5 Hz, H6);
13C (125MHz, CDCl3): δ 164.54 (C7), 138.51 (C4), 129.12 (C2),
123.81 (C1), 116.12 (C3), 37.99 (C5), 36.02 (C6);
MS (ESI) m/z 148.1 [M+H]+
HRMS m/z (ESI+) calcd for C9H10NO [M+H]+: 148.0757, found
148.0464 (6.5 ppm).
Analysis is in agreement with the literature.19
3.4. Synthesis of (E)-4-(dimethylamino)-N-phenyl-but-2-enamide (10)
(E)-4-(dimethylamino)but-2-enoic acid hydrochloride (133.4mg,
0.805mmol, 1.5 equ) was dissolved in THF (5ml) with triethylamine
(217.3mg, 2.15mmol, 4 equ) and T3P (683mg, 1.07mmol, 2 equ)
(50% in Ethyl acetate (0.6400ml)) was added. After 15min aniline
(50mg, 0.54mmol, 1 equ) was added and the reaction stirred over-
night. Then 10ml saturated sodium hydrogen carbonate solution was
added and the solution extracted 3× with 10ml DCM. The combined
organic layers were dried over MgSO4, passed through a phase se-
parator and evaporated to dryness. The residue was purified by flash
chromatography eluting with a gradient of 0–9% methanol in DCM to
give a mixture containing (E)-4-(dimethylamino)-N-phenyl-but-2-en-
amide (46mg) as a pale yellow powder. This was purified by HPLC
eluting with 5–95% acetonitrile in water (0.1% NH4) to give (E)-4-
(dimethylamino)-N-phenyl-but-2-enamide (41mg, 37%) as a white
powder.
1H (400MHz, CDCl3): δ 7.92 (1H, brs, H5), 7.57 (2H, d, J=7.7 Hz,
H3), 7.28 (2H, t, J=7.9 Hz, H2), 7.08 (1H, t, J=7.3 Hz, H1), 6.94
(1H, dt, J=15.3, 6.1 Hz, H8), 6.14 (1H, dt, J=15.3, 1.6 Hz, H7), 3.04
(2H, dd, J=6.1, 1.5 Hz, H9), 2.23 (6H, s, H10);
13C (100MHz, CDCl3): δ 142.83 (C8), 129.20 (C2), 125.76 (C7),
124.56 (C1), 119.95 (C3), 60.53 (C9), 45.71 (C10)
HRMS m/z (ESI+) calcd for C12H17N2O [M+H]+: 205.1335, found
205.1350 (4.6 ppm).
3.5. Synthesis of 1-phenylprop-2-yn-1-ol (17)
Benzaldehyde (200mg, 1.88mmol, 1 equ) was dissolved in THF
(20ml) and bromo(ethynyl)magnesium (292mg, 2.26mmol, 1.2 equ)
(0.5M in THF) was added dropwise over 10min and the reaction stirred
at 0 °C for 30min. The reaction was then allowed to warm up to room
temperature and stirred for three hours. 10ml saturated ammonium
chloride solution was added and stirred vigorously. 10ml Ethyl acetate
was added and the layers separated, the aqueous layer was extracted
2× with 10ml ethyl acetate. The combined organic layers were washed
with 10ml water, 10ml brine, dried over MgSO4 and evaporated to
dryness. The residue was purified by flash chromatography with a
gradient of 0–40% ethyl acetate in heptane to give 1-phenylprop-2-yn-
1-ol (204mg, 82%) as a colourless oil.
1H (400MHz, CDCl3): δ 7.55 (2H, m, H2), 7.38 (3H, m, H1, H3),
5.43 (1H, dd, J=5.0 2.0 Hz, H5), 3.42 (1H, d, J=5.2 Hz, OH), 2.68
(1H, d, J=2.3 Hz, H7).
Analysis is in agreement with the literature.20
3.6. Synthesis of 1-phenylprop-2-yn-1-one (11)
1-phenylprop-2-yn-1-ol (17) (191mg, 1.45mmol, 1 equ) was dis-
solved in DCM (15ml) and cooled to 0 °C. Dess-Martin (674mg,
1.59mmol, 1.1 equ) was added and the reaction stirred while slowly
warming up to room temperature. When TLC indicated the reaction was
complete 20ml saturated sodium thiosulfate solution was added, the
layers separated and the organic layer washed with 20ml saturated
sodium thiosulfate solution. The aqueous layers were combined and
extracted 2× with 15ml DCM. The combined organics were washed
with saturated sodium hydrogen carbonate solution, brine, dried over
MgSO4, passed through a phase separator and evaporated to dryness.
The residue was purified by flash chromatography eluting with a gra-
dient of 0–50% ethyl acetate in heptane to give 1-phenylprop-2-yn-1-
one (127mg, 68%) as a colourless oil which crystallised on standing.
1H (400MHz, CDCl3): δ 8.17 (2H, d, J=7.9 Hz, H3), 7.64 (1H, t,
J=7.4 Hz, H1), 7.50 (2H, t, J=7.7 Hz, H2), 3.43 (1H, s, H7);
13C (100MHz, CDCl3): δ 177.54 (C5), 136.29 (C4), 134.67 (C1),
129.85 (C3), 128.83 (C2), 80.87 (C7), 80.41 (C6).
Analysis is in agreement with the literature.20
3.7. Synthesis of N-phenylprop-2-enamide (12)
Aniline (100mg, 1.07mmol, 1 equ) and triethylamine (326mg,
3.22mmol, 3 equ) were dissolved in DCM (10ml) and cooled to 0 °C.
Prop-2-enoyl chloride (97mg, 1.07mmol, 1 equ) was added and the
reaction allowed to warm up to room temperature overnight. Methanol
(10ml) was added and stirred for 30min and the reaction was evapo-
rated to dryness. The residue was purified by flash chromatography
eluting with a gradient of 0–50% ethyl acetate in heptane to give N-
phenylprop-2-enamide (103mg, 65%) as a white powder.
1H (400MHz, DMSO‑d6): δ 10.09 (1H, brs, H5), 7.66 (2H, d,
J=8.2 Hz, H3), 7.32 (2H, t, J=7.7 Hz, H2), 7.06 (1H, t, J=7.3 Hz,
H1), 6.44 (1H, dd, J=17.0, 10.1 Hz, H7), 6.25 (1H, dd, J=17.0,
1.8 Hz, H8a), 5.75 (1H, dd, J=10.1, 1.3 Hz, H8b);
13C (100MHz, DMSO‑d6): δ 163.06 (C6), 138.95 (C4), 131.86 (C7),
128.68 (C2), 126.69 (C8), 123.40 (C1), 119.30 (C3);
MS (ESI) m/z 148.1 [M+H]+
HRMS m/z (ESI+) calcd for C9H10NO [M+H]+: 148.0757, found
148.0743 (12.8 ppm).
Analysis is in agreement with the literature.21
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3.8. Synthesis of benzenesulfonyl fluoride (13)
Benzenesulfonyl chloride (150mg, 0.85mmol, 1 equ) was dissolved
in THF (10ml) and tetrabutylammonium fluoride (444mg, 1.7mmol,
2 equ) was added. The reaction was stirred at room temperature over-
night. 5 ml saturated sodium hydrogen carbonate solution and 10ml
water was added and the reaction extracted 3× with 20ml DCM. The
combined organics were dried over MgSO4 and evaporated to dryness.
The residue was purified by flash chromatography eluting with a gra-
dient of 0–80% ethyl acetate in heptane to give benzenesulfonyl
fluoride (66mg, 49%) as a colourless oil.
1H (500MHz, CDCl3): δ 8.01 (2H, m, H3), 7.79 (1H, m, H1), 7.64
(2H, m, H2);
13C (125MHz, CDCl3): δ 135.71 (C1), 133.24 (d, JC-F= 24.4 Hz,
C4), 129.80 (C2), 128.52 (C3).
Analysis is in agreement with the literature.22
3.9. Synthesis of methyl N-phenylcarbamate (14)
Aniline (200mg, 2.15mmol, 1 equ) was dissolved in DCM (25ml)
and cooled to 0 °C. Pyridine (221mg, 2.79mmol, 1.3 equ) was added
followed by methyl chloroformate (244mg, 2.58mmol, 1.2 equ) and
the reaction stirred while slowly warming up to room temperature.
When TLC indicated the reaction was complete 10ml water was added,
the layers separated and the aqueous layer extracted 2× with 15ml
DCM. The combined organics were passed through a phase separator
and evaporated to dryness. The residue was purified by flash chroma-
tography eluting with a gradient of 0–50% ethyl acetate in heptane to
give methyl N-phenylcarbamate (325mg, 100%) as a pale yellow oil.
1H (400MHz, CDCl3): δ 7.38 (2H, d, J=8.0 Hz, H3), 7.31 (2H, t,
J=7.8 Hz, H2), 7.07 (1H, t, J=7.3 Hz, H1), 6.63 (1H, brs, H5), 3.78
(3H, s, H7);
13C (100MHz, CDCl3): δ 154.19 (C6), 138.00 (C4), 129.20 (C2),
123.64 (C1), 118.92 (C3), 52.45 (C7);
HRMS m/z (ESI+) calcd for C8H07NO2 [M+H]+: 152.0706, found
152.0716 (5.9 ppm).
Analysis is in agreement with the literature.23
3.10. Synthesis of N-phenylethenesulfonamide (15)
Aniline (100mg, 1.074mmol, 1 equ) and 2-chloroethanesulfonyl
chloride (175mg, 1.074mmol, 1 equ) were dissolved in DCM (10ml)
and cooled to 0 °C. Triethylamine (326mg, 3.22mmol, 3 equ) was
added and the reaction was stirred for 10min then allowed to warm up
to room temperature. After 2 h TLC suggested no starting material re-
mained so the reaction was quenched with 20ml water and the layers
separated. The aqueous layer was extracted 2× with 20ml DCM, the
combined organics washed with 20ml 1 N HCl, 20ml brine, dried over
MgSO4 and evaporated to dryness. The residue was purified by flash
chromatography eluting with a gradient of 0–50% ethyl acetate in
heptane to give a colourless oil. This was dissolved in 5ml DCM and
5ml heptane was added, the DCM was removed under reduced pres-
sure. A precipitate formed and was isolated by filtration to give N-
phenylethenesulfonamide (196mg, 100%) as off white crystals.
1H (500MHz, CDCl3): δ 7.45 (1H, brs, H5), 7.30 (2H, m, H2), 7.21
(2H, m, H3), 7.14 (1H, m, H1), 6.58 (1H, dd, J=16.5, 10.0 Hz, H6),
6.24 (1H, d, J=16.6 Hz, H7a), 5.91 (1H, d, J=10.0 Hz, H7b);
13C (100MHz, CDCl3): δ 137.76 (C4), 136.25 (C6), 129.14 (C2),
127.55 (C7), 123.80 (C1), 119.70 (C3);
MS (ESI) m/z 184.1 [M+H]+
HRMS m/z (ESI+) calcd for C8H10NO2S [M+H]+: 184.0427, found
184.0430 (5.3 ppm).
Analysis is in agreement with the literature.24
3.11. Synthesis of 1-phenylprop-2-en-1-ol (18)
Benzaldehyde (100mg, 0.94mmol, 1 equ) was dissolved in THF
(10ml) and bromo(vinyl)magnesium (148mg, 1.13mmol, 1.2 equ)
(1M in THF) was added dropwise over 10min and the reaction stirred
at 0 °C for 30min. The reaction was then allowed to warm up to room
temperature and stirred overnight. Then 10ml saturated ammonium
chloride solution was added and stirred vigorously. 10ml ethyl acetate
was added and the layers separated, the aqueous layer was extracted
2× with 10ml ethyl acetate. The combined organic layers were washed
with 10ml water, 10 ml brine, dried over MgSO4 and evaporated to
dryness. The residue was purified by flash chromatography eluting with
a gradient of 0–80% ethyl acetate in heptane to give 1-phenylprop-2-en-
1-ol (118mg, 93%).
1H (400MHz, CDCl3): δ 7.23 (4H, d, J=4.4 Hz, H2, H3), 7.17 (1H,
m, H1), 5.90 (1H, ddd, J=17.1, 10.3, 6.0 Hz, H6), 5.20 (1H, dt,
J=17.1, 1.4 Hz, H7a), 5.05 (1H, dt, J=10.3, 1.3 Hz, H7b), 5.02 (1H,
d, J=5.9 Hz, H5).
Analysis is in agreement with the literature.25
3.12. Synthesis of 1-phenylprop-2-en-1-one (16)
1-phenylprop-2-en-1-ol (18) (216mg, 1.61mmol, 1 equ) was dis-
solved in DCM (15ml) and cooled to 0 °C. Dess-Martin (751mg,
1.78mmol, 1.1 equ) was added and the reaction stirred while slowly
warming up to room temperature.
When TLC indicated the reaction was complete 20ml saturated
sodium thiosulfate solution was added, the layers separated and the
organic layer washed with 20ml saturated sodium thiosulfate solution.
The aqueous layers were combined and extracted 2× with 15ml DCM.
The combined organics were washed with saturated sodium hydrogen
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carbonate solution, brine, dried over MgSO4, passed through a phase
separator and evaporated to dryness.
The residue was purified by flash chromatography eluting with a
gradient of 0–50% ethyl acetate in heptane to give 1-phenylprop-2-en-
1-one (200mg, 94%) as a colourless oil. Despite the product being
stored in the freezer it was observed to have turned brown when needed
so was repurified by flash chromatography (12 g column) eluting with a
gradient of 0–2% methanol in DCM to give 1-phenylprop-2-en-1-one
(43mg, 20%) yield as a colourless oil.
1H (400MHz, CDCl3): δ 7.93 (2H, m, H3), 7.55 (1H, m, H1), 7.45
(2H, m, H2), 7.14 (1H, dd, J=17.1, 10.6 Hz, H6), 6.42 (1H, dd,
J=17.1, 1.7 Hz, H7a), 5.90 (1H, dd, J=10.6, 1.7 Hz, H7b);
13C (100MHz, CDCl3): δ 191.07 (C5), 137.27 (C4), 133.03 (C1),
132.38 (C6), 130.22 (C7), 128.72 (C2), 128.65 (C3).
Analysis is in agreement with the literature.26
3.13. Synthesis of Boc-Arg-OMe (19)
2-(tert-butoxycarbonylamino)-5-guanidino-pentanoic acid (100mg,
0.36mmol, 1 equ) and N,N′-dicyclohexylmethanediimine (83mg,
0.40mmol, 1.1 equ) were dissolved in DCM (4ml) with N,N-di-
methylpyridin-4-amine (4.5 mg, 0.04mmol, 0.1 equ). Methanol (74 µL,
1.83mmol, 5 equ) was added and the reaction stirred for five days.
LCMS indicated the reaction was complete so it was filtered and eva-
porated to dryness. The residue was purified by flash chromatography
eluting with a gradient of 0–10% methanol in DCM followed by HPLC
5–95% acetonitrile in water (0.1% HCOOH) to give methyl 2-(tert-bu-
toxycarbonylamino)-5-guanidino-pentanoate (56mg, 53%) as a col-
ourless oil.
1H (400MHz, CDCl3): δ 8.19 (1H, brs, NH), 7.18 (4H, brs, NHs),
4.21 (1H, brs, H3), 3.73 (3H, s, H1), 3.30 (2H, brs, H6a, NH), 3.19 (1H,
m, H6b), 1.84 (1H, brs, H4a), 1.69 (3H, brs, H4b, H5), 1.41 (9H, s,
H14);
13C (100MHz, CDCl3): δ 169.64 (C2), 157.75 (C8), 156.37 (C12),
80.39 (H13), 52.99 (C3), 52.69 (C1), 40.93 (C6), 29.92 (C4), 28.49
(C14), 25.07 (C5);
HRMS m/z (ESI+) calcd for C12H25N4O4 [M+H]+: 289.1870, found
289.1874 (1.3 ppm).
3.14. NMR assay
To 0.5ml of the assay buffer (100mM PBS in 90% H2O:10% D2O)
was added 5 μl of the covalent warhead (0.2M in DMSO‑d6), in an NMR
tube and a 1H NMR spectra was acquired. To 0.5ml of the same buffer
was added 5 μl of the amino acid (2M in DMSO‑d6). This was added to
the NMR tube and the solution mixed by inverting the tube several
times. If necessary, sonication was used to ensure complete dissolution.
This gave a final solution of 1mM covalent warhead, 10mM amino acid
in 100mM PBS. A 1H NMR was typically recorded on this sample every
10min for 6 h. In the experiment, there was a ∼4 s data acquisition
time, followed by a 4 s relaxation delay to minimise peak saturation.
Each data point required approximately 2min (16 scans per data point).
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